DELEX aims to close the gaps that many patients experience in coping in the ICU (Intensive Care Units) from their health conditions to the high cost of treatments and medicines by providing quality alternative drugs at affordable prices. Over the years, Delex has develop the Strengths and Advantages stated below:
Delex Pharma has received Trademark Approval from the Intellectual Property Office of the Philippines (IPOPH) for 5 of its owned brands – Ceftrex, Delexam, Delexard, Dobulex and Norepin.
Delex Pharma owns the patents and production rights for 5 pharmaceutical products – Ceftazin, Ceftrex, Dobulex, Nicardilex and Norepin. Delex plans to market these products globally, and further develop more product range, its distribution and markets across the world, after its fundraising and or public listing.
4 of the products distributed by Delex Pharma are listed in the Top 200 Hospital Ethical Products, namely: Norepin, Ifimol, Nicardilex and Dobulex.
2 of the products distributed by Delex Pharma – Norepin and Ifimol, have approximately 90% market penetration to the hospitals in the Philippines. Norepin is steadily becoming the market leader in the pharmaceutical market and has been ranked 7th among the top 200 products in the pharmaceutical industry. Ifimol is currently the market leader in the I.V. Paracetamol market.
9 of the products distributed by Delex Pharma – Dobulex, Endurpin, Funginil, Ifimol, Intrafen, Midazolex, Nicardilex, Norepin, and Totilac are top leading brands and market leaders in their respective therapeutic sectors in the Philippines.
Delex Pharma currently distributes a total of 16 product lines covering critical care, anesthesia, and anti-infectives, (excluding its device business), mainly for intensive care settings such as Intensive Care Units, Emergency Rooms, and Operating Theaters.
Delex Pharma holds Certificates of Product Registrations for 5 Critical Care Drugs: Dobulex (Dobutamine), Humal (Human Albumin), Nicardilex (Nicardipine Hydrochloride), Norepin (Norepinephrine), and Totilac (Hypertonic Lactate); 5 Anti-Infectives: Ceftazine (Ceftazidime), Ceftrex (Ceftriaxone), Delexigyl (Metronidazole), Funginil I.V. (Fluconazole), and Linezolid (Axazolid); and 6 Anesthesias: Endurpin (Nalbuphine Hydrochloride), Ifimol I.V. (Paracetamol), Intrafen (Ibuprofen), Keterolex (Keterolac Trometamol), Midazolex (Midazolam), and Tramadex (Tramadol); and several medical devices.
Delex Pharma currently holds various licenses and permits issued by the Philippines Food and Drug administration for (i) Importer/ Wholesaler/Distributor of Drugs (ii) Importer of Medical Devices (iii) Food Wholesaler, (iv) Cosmetic Importer and Wholesaler and (v) Drugstore Operator, including Online Order and Delivery.
Delex Pharma distributes its products to over 5,000 distribution channels including private and government hospitals, drugstore chains, sub-distributors, clinics, dispensing HCPs, etc.
Delex Pharma has appointed several established parties for its various projects and services:
Delex University was established to continuously provide seminars, updates and tools for its employees and external customers. Delex has successfully conducted over 200 ICU Forums and Webinars with over 160,000 viewers.
Delex has also built a database of 100,000 HCPs (Healthcare Providers) from 96 countries since May 2020. This was made possible by partnering with 30 medical societies and hospitals through its online forums and webinars.
The global pharmaceutical market is around US$1.5 trillion in 2022. Worldwide pharmaceutical revenue had seen a steady increase every single year since 2001, when the market’s value was about two-thirds smaller. The largest submarket within this industry has been the United States in recent years. Total pharmaceutical sales in the United States amounted to over $600 billion, according to estimates as of Q3 2022.
According to Global Pharma sales projections for 2025, Southeast Asia and East Asia, excluding Japan and China, will report consolidated sales of over $260 billion, putting the subregion in third place behind North America and the European Union. All major Southeast Asian pharma markets were forecasted to experience medical sales growth in the next few years.
